接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析*

doi:10.3969/j.issn.1672-5069.2019.02.029

摘要/Abstract

摘要： 目的探讨肝细胞癌（HCC）患者血清miR-335水平变化及其在经肝动脉栓塞化疗术（TACE）治疗后,对判断预后的价值。方法 2014年5月~2016年5月收治的HCC患者60例,慢性乙型肝炎患者50例,乙型肝炎肝硬化患者50例和选择的健康人50例,采用实时荧光定量反转录PCR法检测血清miR-335水平。给予HCC患者TACE治疗,并随访2年。计算受试者工作特征（ROC）曲线下面积（AUC）,分析应用血清miR-335水平预测HCC患者预后的价值。结果 HCC患者血清miR-335水平为（1.18±1.35）,显著低于乙型肝炎（1.91±2.11）和肝硬化患者（2.01±0.75）,也显著低于正常人【（2.07±1.25）,P=0.001】,肝硬化和慢性乙型肝炎患者血清miR-335水平与正常人比,差异均无统计学意义（P>0.05）;22例存在门静脉癌栓的HCC患者血清miR-335水平显著低于38例无癌栓患者（t=4.586,P<0.001）,13例死亡患者血清miR-335水平显著低于47例生存患者（t=3.324,P<0.001）,而不同性别、年龄、肿瘤大小、TNM分期、有无淋巴结转移和血清AFP水平高低患者,血清miR-335水平差异无统计学意义（P均>0.05）;随访2年,本组HCC患者死亡13例（21.7%）。以血清miR-335水平小于或等于0.820为截断点,判断患者2年内死亡的敏感性为83.0%,特异度为100.0%。结论 HCC患者血清miR-335水平显著降低,其水平越低,预后越差,该结论需要进一步研究。

关键词: 肝细胞癌, miR-335, 肝动脉栓塞化疗术, 预后

Abstract: Objective To investigate the changes of serum miR-335 levels in patients with hepatocellular carcinoma （HCC） undergoing transcatheter arterial chemoembolization （TACE）. Methods 60 patients with HCC,50 with chronic hepatitis B （CHB）,50 with hepatitis B liver cirrhosis （LC） and 50 healthy persons were recruited in our hospital between May 2014 and May 2016. All patients with HCC received TACE for average three times and followed-up for 24 months. Serum miR-335 levels were detected by real-time quantitative reverse transcription PCR,and the prognosis of patients with HCC by serum miR-335 levels was predicted by the area under the curve of receiver-operating characteristic. Results Serum miR-335 level in patients with HCC was（1.18±1.35）,much lower than （1.91±2.11） in patients with CHB,or （2.01±0.75） in patients with LC,and also significantly lower than【（2.07±1.25）,P=0.001】 in healthy persons;serum miR-335 level in 22 HCC patients with portal vain tumor thrombus was significantly lower than in 38 patients without（t=4.586,P<0.001）,serum miR-335 level in 13 dead patients was much lower than in 47 survivals（t=3.324,P<0.001）,while those in patients with different gender,age,tumor sise,TNM stage,serum AFP levels and with or without lymph node metastasis were not significantly different （all P>0.05）;the sensitivity was 83.0% and the specificity was 100.0% when serum miR-335 level being 0.820 was set for the cut-off-value for predicting the two-year patients’ death. Conclusion Serum miR-335 levels in patients with HCC decrease,and the lower the serum miR-335 levels,the poorer the prognosis,which warrants further investigation.

Key words: Hepatocellular carcinoma, miR-335, Transcatheter arterial chemoembolization, Prognosis

张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.

Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.

参考文献

[1] Goh B,Chow PK,Teo JY,et al.Number of nodules, Child-Pugh status,margin positivity and microvascular invasion but not tumour size are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. Eur J Surg Oncol,2014,18(8):1477.
[2] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肿瘤学杂志,2011,20(10):929-946.
[3] Qu KZ,Zhang K,Li H,et al.Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol,2011,45(4):355.
[4] Liu AM,Yao TJ,Wang W,et al.Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma:a retrospective cohort study. BMJ Open,2012,2:e000825.
[5] Chang-Hao TS,Behren A,Cebon J,et al.The role of circulating microRNA in hepatocellular carcinoma. Front Biosci,2015,20(1):78-104.
[6] Shen J,Wang A,Wang Q,et al.Exploration of genome-wide circulating MicroRNA in hepatocellular carcinoma (HCC):MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev,2013,22(12):2364-2373.
[7] Alessandro S,Edoardo A,Nazario P,et al.Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol,2013,42(2):391.
[8] Alkafaji G,Almahroos G,Alsayed N A,et al.Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol Med Rep,2015,12(5):7485.
[9] Bail S,Swerdel M,Liu H,et al.Differential regulation of microRNA stability. RNA,2010,16(5):1032-1039.
[10] Jung M,Schaefer AI,Kempkensteffen C,et al.Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem,2010,56(6):998-1006.
[11] Connolly EC,Van DK,Rogler LE,et al.Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res,2010,8(5):691-700.
[12] Scisciani C,Vossio S,Guerrieri F,et al.Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol,2012,56(4):855.
[13] Zhang Y,Guo X,Xiong L,et al.MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett,2012,586(24):4362.
[14] Jie X,Zhu X,Wu L,et al.MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int,2012,32(5):752-760.
[15] Xiong SW,Lin TX,Xu KW,et al.MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res,2013,19(3):529-537.
[16] White NM,Bao TT,Grigull J,et al.miRNA profiling for clear cell renal cell carcinoma:biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol,2011,186(3):1077-1083.
[17] Dohi O,Yasui K,Takada H,et al.Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol,2013,42(2):411-418.
[18] 刘志洋,刘伟伟,贾萍,等. 微小RNA-335通过靶定人类表皮生长因子3调控乳腺癌细胞的侵袭. 中华实验外科杂志,2015,32(5):954-958.
[19] 张家魁,谢强,刘继超,等. MiR-335表遗传学调控与胃癌临床病理特征和预后相关性研究. 中华肿瘤防治杂志,2015,22(21):1680-1687.
[20] 王皓,周宇. 微小RNA在肝胆胰疾病中作用的研究进展. 实用肝脏病杂志,2011,14(2):155-157.
[21] 徐伟红,姚怡婷,曹华,等. 血清GP73、AFP-L3、AFP及AFU检测在原发性肝癌诊断中的应用评价. 中华检验医学杂志,2016,39(4):262-266.
[22] 李海军,白杰,丁伟,等. 联合检测血清甲胎蛋白、γ-谷氨酰转肽酶和 α-L-岩藻糖苷酶对肝细胞癌根治术后转移复发的预测价值. 中华实验外科杂志,2009,26(11):1552-1554.

接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*

Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[3]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[4]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[5]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[6]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[7]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[8]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[9]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[10]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[11]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[12]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[13]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[14]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[15]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.